| Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481). | |
| | |
MedLine Citation:
|
PMID: 11426558 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Thirty-three evaluable patients with Hodgkin's disease who failed radiotherapy were treated on this phase II study with bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone given every 28 days for a minimum of eight courses. Twenty-five patients (76%; 95% CI=55.6-87.1%) achieved a complete remission, the median duration of which cannot yet be determined, but the probability of remaining in continuous complete remission at 10 years is.64. The median survival from entry on this study for all evaluable patients is 10 years, and 12 patients were alive at the time of this analysis with a median follow-up for them of 15.5 years. Of the 22 patients who died, 11 died of progressive or recurrent Hodgkin's disease and 11 died of other causes including 7 second primary neoplasms and at least one myocardial infarction. Both are now well known late complications of Hodgkin's disease treatment. |
| | |
Authors:
|
P H Wiernik; T Leong; M M Oken; R S Neiman; T M Habermann; J M Bennett; S Schuster; J H Glick |
Related Documents
:
|
16254628 - Hemogram and myelogram in progressing non-hodgkin's lymphomas. 8649058 - Hodgkin's disease: from basic science to clinical application. 19125088 - Successful treatment of hodgkin lymphoma in nijmegen breakage syndrome. 301608 - Impaired humoral immunity in treated hodgkin's disease. 12594938 - Endometrial cancer: treatment of nodal metastases. 15895378 - Outcomes and prognostic factors after recurrence in children and adolescents with nonme... |
Publication Detail:
|
Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Leukemia & lymphoma Volume: 40 ISSN: 1042-8194 ISO Abbreviation: Leuk. Lymphoma Publication Date: 2001 Jan |
Date Detail:
|
Created Date: 2001-06-27 Completed Date: 2002-02-21 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 9007422 Medline TA: Leuk Lymphoma Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 357-63 Citation Subset: IM |
Affiliation:
|
OLM Comprehensive Cancer Center, New York Medical College, Bronx 10466, USA. wiernik@jimmy.harvard.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Antineoplastic Combined Chemotherapy Protocols / administration & dosage*, toxicity Bleomycin / administration & dosage, toxicity Cause of Death Cohort Studies Cyclophosphamide / administration & dosage, toxicity Female Hodgkin Disease / complications, drug therapy*, mortality Humans Lomustine / administration & dosage, toxicity Lymphatic Irradiation Male Middle Aged Prednisone / administration & dosage, toxicity Procarbazine / administration & dosage, toxicity Recurrence Survival Analysis Treatment Outcome Vincristine / administration & dosage, toxicity |
| Grant Support | |
ID/Acronym/Agency:
|
CA11083/CA/NCI NIH HHS; CA13650/CA/NCI NIH HHS; CA15488/CA/NCI NIH HHS; CA21115/CA/NCI NIH HHS; CA23318/CA/NCI NIH HHS; CA49883/CA/NCI NIH HHS; CA66636/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
11056-06-7/Bleomycin; 13010-47-4/Lomustine; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 57-22-7/Vincristine; 671-16-9/Procarbazine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lack of correlation between clinical characteristics and serum soluble Fas ligand levels in patients...
Next Document: Vascular access via peripherally inserted central venous catheters (PICCs): experience in 40 patient...